000165622 001__ 165622
000165622 005__ 20260112132217.0
000165622 0247_ $$2doi$$a10.1111/resp.14223
000165622 0248_ $$2sideral$$a147103
000165622 037__ $$aART-2022-147103
000165622 041__ $$aeng
000165622 100__ $$aEzponda, Ana
000165622 245__ $$aChest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort
000165622 260__ $$c2022
000165622 5203_ $$aAbstractBackground and objectiveThe availability of chest computed tomography (CT) imaging can help diagnose comorbidities associated with chronic obstructive pulmonary disease (COPD). Their systematic identification and relationship with all‐cause mortality have not been explored. Furthermore, whether their CT‐detected prevalence differs from clinical diagnosis is unknown.MethodsThe prevalence of 10 CT‐assessed comorbidities was retrospectively determined at baseline in 379 patients (71% men) with mild to severe COPD attending pulmonary clinics. Anthropometrics, smoking history, dyspnoea, lung function, exercise capacity, BODE (BMI, Obstruction, Dyspnoea and Exercise capacity) index and exacerbations rate were recorded. The prevalence of CT‐determined comorbidities was compared with that recorded clinically. Over a median of 78 months of observation, the independent association with all‐cause mortality was analysed. A ‘CT‐comorbidome’ graphically expressed the strength of their association with mortality risk.ResultsCoronary artery calcification, emphysema and bronchiectasis were the most prevalent comorbidities (79.8%, 62.7% and 33.9%, respectively). All were underdiagnosed before CT. Coronary artery calcium (hazard ratio [HR] 2.09; 95% CI 1.03–4.26, p = 0.042), bronchiectasis (HR 2.12; 95% CI 1.05–4.26, p = 0.036) and low psoas muscle density (HR 2.61; 95% CI 1.23–5.57, p = 0.010) were independently associated with all‐cause mortality and helped define the ‘CT‐comorbidome’.ConclusionThis study of COPD patients shows that systematic detection of 10 CT‐diagnosed comorbidities, most of which were not detected clinically, provides information of potential use to patients and clinicians caring for them.
000165622 540__ $$9info:eu-repo/semantics/closedAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000165622 590__ $$a6.9$$b2022
000165622 591__ $$aRESPIRATORY SYSTEM$$b12 / 66 = 0.182$$c2022$$dQ1$$eT1
000165622 592__ $$a1.294$$b2022
000165622 593__ $$aPulmonary and Respiratory Medicine$$c2022$$dQ1
000165622 594__ $$a9.4$$b2022
000165622 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165622 700__ $$aCasanova, Ciro
000165622 700__ $$aDivo, Miguel
000165622 700__ $$0(orcid)0000-0003-0777-3850$$aMarín-Oto, Marta$$uUniversidad de Zaragoza
000165622 700__ $$aCabrera, Carlos
000165622 700__ $$aMarín, José M.
000165622 700__ $$aBastarrika, Gorka
000165622 700__ $$aPinto-Plata, Víctor
000165622 700__ $$aMartin-Palmero, Ángela
000165622 700__ $$aPolverino, Francesca
000165622 700__ $$aCelli, Bartolomé R.
000165622 700__ $$aTorres, Juan P. de
000165622 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000165622 773__ $$g27, 4 (2022), 286-293$$pRespirology$$tRESPIROLOGY$$x1323-7799
000165622 8564_ $$s3787758$$uhttps://zaguan.unizar.es/record/165622/files/texto_completo.pdf$$yVersión publicada
000165622 8564_ $$s2529295$$uhttps://zaguan.unizar.es/record/165622/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165622 909CO $$ooai:zaguan.unizar.es:165622$$particulos$$pdriver
000165622 951__ $$a2026-01-12-11:11:25
000165622 980__ $$aARTICLE